Aditiawarman, - and Jacob Trisusilo Salean, - and Mahendra Tri Arif Sampurna, - and Ernawati, - and Hermanto Tri Joewono, - (2020) Comparison of short-term outcome and serum magnesium levels in premature infants of mothers after magnesium sulfate therapy. EurAsian Journal of BioSciences, 14 (1). pp. 1863-1867. ISSN 1307-9867

	Text (Artikel) Artikel 15.pdf Download (320kB)
	Text (Karil) Karil 15.pdf Download (168kB)
	Text (Similarity) Similarity 15.pdf Download (1MB)
	Text (Artikel) 17. artikel.pdf Download (3MB)

Abstract

Background: Magnesium sulfate (MgSO4) is proven to be a neuroprotectant which functions to reduce the risk of cerebral palsy in premature infants, but the effects on the short-term outcome of newborns are still contradictory. This study aimed to analyze differences in short-term outcomes and serum magnesium levels in newborns after given MgSO4 therapy. Methods: This was a prospective cohort study. Subjects were divided into two groups involved preterm infants from mothers who received MgSO4 and pregnant women who did not received MgSO4 as a control. Results: Among sixty subjects, there were significant differences in outcomes for gestational age infants and respiratory distress syndrome (RDS) between two groups (p = 0.011 and p = 0.013, respectively). Whereas, the significance results were found in birth weight (p = 0.306), Apgar scores 1 (p = 0.816) and 5 minutes (p = 0.924), the use of ventilators (p = 0.335), sepsis (p = 0.276), mortality (p = 0.754), and umbilical artery pH (p = 0.123). The magnesium serum levels of mothers who received MgSO4 and control were 3.45±1.65 mg/dl and 1.78±0.23 mg/dl, respectively (p = 0.001), and infants who received MgSO4 and control were 3.10±1.35 mg/dl and 1.74±0.19 mg/dl, respectively (p = 0.001). Conclusion: There were significant differences in infant outcomes only at gestational age and RDS. The magnesium serum levels of newborns in therapy group were higher than control.

Actions (login required)

View Item